Volume 30, Number 5—May 2024
Research Letter
SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023
Yaniv Lustig
, Michal Canetti, Victoria Indenbaum, Yovel Peretz, Yael Weiss-Ottolenghi, Ili Margalit, Keren Asraf, Tal Levin, Neta Zuckerman, Enosh Tomer, Michal Mandelboim, Ram Doolman, Noam Barda, and Gili Regev-Yochay
, Michal Canetti, Victoria Indenbaum, Yovel Peretz, Yael Weiss-Ottolenghi, Ili Margalit, Keren Asraf, Tal Levin, Neta Zuckerman, Enosh Tomer, Michal Mandelboim, Ram Doolman, Noam Barda, and Gili Regev-Yochay
Table
Sex, age range, and COVID-19 history of patient participants who provided samples for testing IgG against SARS-CoV-2 ancestral strain and Omicron XBB-specific neutralizing antibody levels in 2022 and 2023, Israel*
| Variable | Value |
|---|---|
| Sex | |
| F | 251 (67) |
| M |
122 (33) |
| No. COVID-19 vaccinations received | |
| 0 | 1 (0.3) |
| 1 | 13 (3.5) |
| 2 | 5 (1.3) |
| 3 | 102 (27) |
| 4 | 215 (58) |
| 5 | 36 (9.7) |
| 6 |
1 (0.3) |
| No. COVID-19 infections | |
| 0 | 227 (61) |
| 1 | 120 (32) |
| 2 | 22 (5.9) |
| 3 | 3 (0.8) |
| 4 | 1 (0.3) |
*Values are no. (%) except as indicated.
Page created: April 08, 2024
Page updated: April 24, 2024
Page reviewed: April 24, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.